ZYBT

Zhengye Biotechnology Holding Limited
CAPPED RATING

Zhengye Biotechnology Holding Limited (ZYBT) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -3.4
Rev Growth YoY -40.9%
Gross Margin 20.5%
Price Return 3M -1.3%
Price Return 12M -30.6%
Catalyst Signal 0.00
Market Cap $71.1M
TTM Revenue $116.4M
Price / Sales 0.6
ROE -25.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) D- (0.9) C+ (2.7) B (3.5) C+ (2.6) C+ (2.5)
2026-11-08 B- (3.0) D- (0.8) C+ (2.7) C+ (2.7) C+ (2.6) C (2.4)
2026-11-01 B- (3.0) D- (0.8) C+ (2.7) B- (3.1) C+ (2.7) C (2.5)
2026-10-25 B- (3.0) D- (0.8) C+ (2.7) B- (3.0) C+ (2.6) C (2.4)
2026-10-18 B- (3.0) D- (0.8) C+ (2.7) D+ (1.7) C+ (2.6) C (2.2)
Page 1 of 4